PX1 Research supplies USA-manufactured IGF-1 DES (Des(1-3)IGF-1) synthesized to rigorous academic and industrial standards. Every batch undergoes exhaustive analytical validation—including RP-HPLC purity assessment, mass spectrometry sequence verification, and LAL endotoxin testing—ensuring reliable, reproducible data in preclinical research applications.
PX1 Research supplies USA-manufactured IGF-1 DES (Des(1-3)IGF-1) synthesized to rigorous academic and industrial standards. Every batch undergoes exhaustive analytical validation—including RP-HPLC purity assessment, mass spectrometry sequence verification, and LAL endotoxin testing—ensuring reliable, reproducible data in preclinical research applications.
Investigators evaluating options when sourcing IGF-1 DES for sale must prioritize analytical transparency, structural integrity, and lot-to-lot consistency. IGF-1 DES—chemically designated as Des(1-3)IGF-1—is a naturally occurring, truncated splice variant of human insulin-like growth factor 1 lacking the N-terminal tripeptide tri-sequence Gly-Pro-Glu. This structural alteration dramatically modifies its binding kinetics, making it a pivotal tool for in vitro cellular culture, signal transduction assays, and preclinical tissue regeneration models.
Because truncated peptide sequences are exceptionally sensitive to improper synthesis, residual TFA (trifluoroacetic acid) accumulation, and cleavage errors during solid-phase peptide synthesis (SPPS), procuring research-grade materials from verified suppliers is essential. At PX1 Research, every lot of IGF-1 DES is manufactured in USA-based, GMP-compliant facilities and tested by an independent ISO 17025 accredited laboratory. Researchers receive full access to lot-specific Certificates of Analysis (COAs) detailing analytical purity via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), molecular weight confirmation via Electrospray Ionization Mass Spectrometry (ESI-MS), and quantification of residual bacterial endotoxins.
Native full-length IGF-1 is a 70-amino-acid polypeptide stabilized by three intrachain disulfide bonds. In contrast, IGF-1 DES is a 67-amino-acid truncated analog generated by the enzymatic cleavage of the N-terminal Gly-Pro-Glu residue sequence. In biological systems, this truncation occurs naturally in tissues such as the porcine brain, human uterine fluids, and specific colostrum fractions.
From a structural biochemistry perspective, the removal of the N-terminal tripeptide alters the electrostatic charging and steric configuration of the binding domain responsible for interacting with circulating IGF-binding proteins (IGFBPs). In vitro bioassays published in the research library demonstrate that while native IGF-1 exhibits high affinity for IGFBP-1 through IGFBP-6, IGF-1 DES exhibits near-zero affinity for these regulatory carrier proteins. Consequently, when introduced to extracellular media or cellular microenvironments, IGF-1 DES remains almost entirely in its unbound, biologically active free state, providing an unattenuated signal to the Type 1 IGF Receptor (IGF-1R).
The primary mechanism of action for Des(1-3)IGF-1 centers on its selective activation of the IGF-1R, a heterotetrameric transmembrane receptor tyrosine kinase. Upon binding to the extracellular alpha-subunits of IGF-1R, IGF-1 DES induces autophosphorylation of intracellular beta-subunit tyrosine residues. This event triggers two primary downstream intracellular cascades: the Phosphoinositide 3-Kinase (PI3K) / Akt pathway and the Mitogen-Activated Protein Kinase (MAPK) / ERK pathway.
In preclinical cell culture experiments, activation of the PI3K/Akt axis by IGF-1 DES promotes protein translation via mammalian target of rapamycin (mTOR) complex 1 (mTORC1) and inhibits pro-apoptotic factors such as BAD and FOXO transcription factors. Concurrently, activation of the MAPK/ERK pathway stimulates cellular proliferation, DNA synthesis, and mitogenesis. Preclinical studies suggest that because IGF-1 DES is not sequestered by IGFBPs, its peak receptor occupancy occurs significantly faster than full-length IGF-1, making it a critical research compound for investigating rapid, localized metabolic and hypertrophic responses in target tissues.
Academic literature spanning several decades highlights the utility of Des(1-3)IGF-1 across various experimental paradigms. In skeletal muscle biology, rodent myoblast models (such as C2C12 cell lines) demonstrate that exposure to IGF-1 DES enhances the rate of myotube formation, increases intracellular amino acid uptake, and upregulates contractile protein synthesis far more rapidly than equivalent concentrations of wild-type growth factors. For detailed insights into these signaling cascades, review our comprehensive paper on growth factor signaling in vitro.
In neurobiological research, preclinical murine models of ischemic injury and neurodegeneration have utilized IGF-1 DES to evaluate survival mechanisms in cortical and hippocampal neurons. In vitro data indicate that the lack of IGFBP binding enables IGF-1 DES to penetrate local tissue matrices where endogenous IGFBPs are hyper-expressed as an injury response. Furthermore, researchers investigating mammalian cell culture optimization often utilize Des(1-3)IGF-1 in serum-free formulations to precisely quantify growth factor consumption without interference from endogenous carrier proteins present in bovine serum serum fractions.
When designing preclinical trials, investigators must choose the appropriate somatomedin analog based on half-life, receptor affinity, and localized versus systemic kinetic requirements. Understanding the operational differences between truncated and extended variants is essential for accurate assay design across all research peptides.
While IGF-1 DES features an N-terminal 3-amino-acid deletion yielding a shortened half-life and intense, localized receptor binding, IGF-1 LR3 incorporates an 83-amino-acid sequence with a glutamic acid-to-arginine substitution at position 3 and a 13-amino-acid N-terminal extension. This structural modification gives IGF-1 LR3 a prolonged half-life (exceeding 20 hours in rodent models) and systemic bioavailability. Conversely, mechanistically distinct compounds such as MGF (Mechano-Growth Factor) and its pegylated variant PEG-MGF act through unique splice-variant pathways specific to localized tissue strain and satellite cell activation rather than direct endocrine IGF-1R stimulation. Researchers targeting systemic growth hormone secretion mechanisms may also evaluate secretagogues like CJC-1295 alongside direct recombinant growth factors.
Proper handling of lyophylized growth factors is critical to prevent aggregation, surface adsorption, and peptide denaturation. IGF-1 DES is supplied as a sterile, lyophilized cake containing minimal excipients. Because of its hydrophobic region exposure, standard aqueous buffers at neutral pH (such as PBS at pH 7.4) may cause immediate precipitation or adsorption to standard glass and polypropylene vial walls.
To properly solubilize lyophilized IGF-1 DES for bench work, researchers should reconstitute the compound using sterile 10 mM to 100 mM acetic acid (pH ~2.5–3.0) or dilute 0.1 M HCl to achieve a concentration between 0.1 mg/mL and 1.0 mg/mL. Once fully dissolved, solution stability can be preserved by adding a carrier protein such as 0.1% Bovine Serum Albumin (BSA) or Human Serum Albumin (HSA) prior to diluting into neutral culture media. For precise stoichiometric calculations, researchers should utilize our peptide reconstitution calculator guide. Reconstituted stock solutions stored at -20°C or -80°C maintain chemical stability for extended research durations, provided freeze-thaw cycles are strictly minimized.
Selecting a trustworthy vendor when evaluating igf-1 des for sale requires analyzing verifiable analytical data rather than unbacked purity claims. Impurities in synthetic peptides—such as truncated deletion sequences, diastereomers, residual TFA, and heavy metals—can confound experimental cell viability assays, alter receptor affinity curves, and trigger false inflammatory responses in animal models.
PX1 Research mandates rigorous batch testing standards prior to releasing any material for laboratory distribution:
1. Reverse-Phase HPLC (RP-HPLC): Quantifies chemical purity by separating the main peak from synthesis side-products. PX1 guarantees >98% chromatographic purity.
2. Electrospray Ionization Mass Spectrometry (ESI-MS): Confirms exact monoisotopic mass (theoretical molecular weight of 7,372.4 Da for Des(1-3)IGF-1), validating correct sequence synthesis.
3. Limulus Amebocyte Lysate (LAL) Endotoxin Assay: Quantifies lipopolysaccharide (LPS) contamination. PX1 Research enforces strict limits (<0.01 EU/mg) to prevent non-specific immune pathway activation in delicate cell cultures.
4. Lot-Specific Traceability: Every vial is serialized, corresponding directly to published analytical COAs accessible to university laboratories, biotech institutes, and commercial procurement departments.
In addition to analytical purity, supply chain stability is essential for ongoing longitudinal studies. PX1 Research operates USA-based manufacturing and logistics infrastructure, with centralized distribution centers in California and Arizona. Orders placed Monday through Friday before cut-off times are dispatched same-day, eliminating project delays caused by overseas transit and customs holds.
For academic departments, contract research organizations (CROs), and industrial laboratories requiring ongoing bulk supply, PX1 offers structured procurement channels. Principal investigators and lab managers can establish dedicated accounts through our wholesale peptide portal, ensuring priority lot reservation, volume pricing, and custom synthesis options tailored to specialized experimental parameters.
What is the chemical difference between IGF-1 DES and native IGF-1?
IGF-1 DES (Des(1-3)IGF-1) is a 67-amino-acid truncated variant of native human IGF-1 (70 amino acids) lacking the N-terminal tripeptide sequence Gly-Pro-Glu. This structural truncation eliminates binding affinity for IGF-binding proteins (IGFBPs), allowing the peptide to interact directly with the Type 1 IGF receptor without systemic protein sequestration.
How should IGF-1 DES be reconstituted for laboratory research?
Lyophilized IGF-1 DES should first be dissolved in a dilute acid solution, such as sterile 10–100 mM acetic acid (pH 2.5–3.0), to prevent aggregation and precipitation. Once in solution, it can be diluted into working buffers containing 0.1% BSA or HSA to minimize non-specific binding to container walls.
What analytical verification accompanies PX1 Research peptides?
Every batch of IGF-1 DES includes a lot-specific Certificate of Analysis (COA) generated by an independent ISO 17025 accredited laboratory. Testing includes RP-HPLC (verifying >98% purity), ESI-Mass Spectrometry (confirming sequence mass), and LAL assay endotoxin testing (<0.01 EU/mg).
Why is low endotoxin content critical for in vitro research with IGF-1 DES?
Bacterial endotoxins (lipopolysaccharides) alter cell culture dynamics by stimulating TLR4 receptors and triggering inflammatory cytokine cascades. Low endotoxin levels (<0.01 EU/mg) ensure that cellular responses measured in vitro are attributable strictly to IGF-1R receptor signaling rather than background immune activation.
What is the half-life of IGF-1 DES compared to IGF-1 LR3 in preclinical models?
Preclinical data show that IGF-1 DES has a short clearance window (approximately 20–30 minutes) due to its lack of IGFBP binding. In contrast, IGF-1 LR3 features a extended half-life exceeding 20 hours because of its N-terminal extension and altered clearance kinetics.
How should lyophilized and reconstituted IGF-1 DES be stored?
Lyophilized IGF-1 DES should be stored in a freezer at -20°C or -80°C away from light. Once reconstituted in dilute acetic acid with a carrier protein, stock aliquots should be frozen at -80°C to avoid repeated freeze-thaw degradation.
Where are PX1 Research peptides manufactured and dispatched from?
All PX1 Research compounds are manufactured in USA-based, GMP-compliant facilities and dispatched directly from centralized distribution hubs in California and Arizona with same-day shipping on weekday orders.
Can institutions purchase IGF-1 DES in bulk for large-scale studies?
Yes, PX1 Research provides institutional accounts, bulk pricing, and custom synthesis support for universities, CROs, and industrial biotech facilities through our dedicated wholesale procurement program.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.